Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Male and Female subjects,12-17 years old * Receiving CNI-based maintenance immunosuppression since the time of renal transplantation in accordance with local standard of care * Stable renal function, in the opinion of the investigator, with a cGFR\>45 mL/min/1.73m2 at the time of enrollment (per updated Schwartz Formula) * Adolescent Recipients of a renal allograft from a living donor or a deceased donor at least 6 months prior to enrollment * Subject must be receiving a calcineurin inhibitor (CNI)-based \[cyclosporine (CsA) \[any formulation\] or Tacrolimus (TAC)\] immunosuppressive regimen * Subject must be receiving adjunctive background maintenance immunosuppression with mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS)/mycophenolic acid (MPA) * Subjects may be receiving maintenance corticosteroids in accordance with the local standard of care * Negative Interferon Gamma Release Assay (IGRA) such as QuantiFERON-TB Gold test or T-Spot-TB * FOCBP must have negative serum or urine pregnancy test within 24 hrs prior to start of study medication * Subject must have stable estimated glomerular filtration rate (GFR) ≥45 mL/min/1.73m2 (updated Schwartz formula) Exclusion Criteria: * Epstein-Barr virus (EBV) serostatus negative or unknown at time of transplant and screening * History of any treated or biopsy proven acute rejectio…